Download announcement as PDF
Thor Medical ASA: First Customer Delivery Completed from AlphaOne
2026-08-05 07:00:25
5.8.2026 07:00:07 CEST | Thor Medical ASA | Non-regulatory press releases
Thor Medical, a leading supplier of high-purity isotopes to the
radiopharmaceutical industry, today announced that it has completed its first
customer delivery of high-purity Thorium-228 from the AlphaOne production
facility at Herøya Industrial Park.
The delivery follows the production start announced last week and marks the
beginning of commercial supply from AlphaOne.
"Commercial production marks the start of industrial-scale manufacturing. Our
first customer delivery marks the beginning of our industrial-scale business,"
said Jasper Kurth, Chief Executive Officer of Thor Medical. "This delivery
demonstrates that we have successfully transitioned from building production
capacity to serving customers from our first industrial-scale facility. As we
continue to ramp production, we are well positioned to support the growing
demand for high-purity isotopes in targeted alpha therapies."
Thor Medical expects customer deliveries from AlphaOne to continue, while
production volumes gradually increase in line with the ramp-up plan towards
21,000 patient dose equivalents after three years.
CONTACTS
* Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988
05 724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies.
Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor
isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally
occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit
www.thormedical.com - http://www.thormedical.com.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19011806/14588/Download%20announc
ement%20as%20PDF.pdf
o/ir-files/17848634/19011806/14588/Download%20announc\
ement%20as%20PDF.pdf\